Redmile Group, LLC, Director, 10% Owner at FATE THERAPEUTICS INC (FATE), bought 1,744,630 shares at $3.72 ($6.5M) on 2023-12-26, disclosed to the SEC on 2023-12-28.
Open-market purchase of $6.5M FATE by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.72 | 44,630 | $166K | 2.6% |
| 2 | $3.72 | 44,630 | $166K | 2.6% |
| 3 | $3.72 | 1,655,370 | $6.2M | 94.9% |
| Total | $3.72 avg | 1,744,630 | $6.5M | 100% |
| Filing → |
| IGMS | SELL | 2023-07-03 | $1.5M | — | Filing → |
| IGMS | BUY | 2023-07-03 | $1.5M | — | Filing → |
| ZYME | BUY | 2022-10-18 | $153K | — | Filing → |